Pacific Biosciences stock falls 11.73 percent to USD 1.73 on October 16, 2026
Published on 10/17/2026 at 19:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and trading metrics
- Pacific Biosciences declined 11.73 percent on October 16, 2026.
- Simply Wall St lifted its fair value estimate to USD 2.40 on October 8, 2026.
- Pacific Biosciences stock last traded at USD 1.73 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 11.73 percent on the day.
- PacBio is scheduled to report third-quarter 2026 results on November 4, 2026.
Pacific Biosciences stock (ISIN US69404D1081) fell 11.73 percent on Nasdaq to USD 1.73 on October 16, 2026. The move followed a sharp retreat from the previous session's USD 1.96 close, while no causal explanation is attached to the price move here. The next valuation marker comes from a fair value estimate of USD 2.40.
Fair value moves to USD 2.40
On October 8, 2026, Yahoo Finance reported that Simply Wall St raised its fair value estimate for Pacific Biosciences from USD 2.16 to USD 2.40. At USD 1.73, that estimate sits 38.73 percent above the Nasdaq price.
The same report cited a Neutral rating and a USD 1.35 price target from UBS. That target is 22.00 percent below the USD 1.73 Nasdaq price, creating a wide gap between the valuation estimate and the named analyst target.
Price position after the decline
The latest Nasdaq price is USD 1.73, with a 52-week range of USD 1.07 to USD 3.44. The stock stands 61.68 percent above its 52-week low and 49.71 percent below its 52-week high.
Pacific Biosciences has a market capitalization of USD 537.7 million. Its share price fell 11.73 percent on October 16, while Illumina declined 2.01 percent and Natera fell 2.80 percent over the same session.
Results date and valuation markers
Pacific Biosciences is scheduled to report third-quarter 2026 results on November 4, 2026. The company develops long-read and short-read genetic sequencing technologies for research and clinical applications.
For investors, the key tension is numerical rather than promotional: the USD 2.40 fair value estimate is materially above the USD 1.73 market price, while the UBS target of USD 1.35 points in the opposite direction.
Comparison with peers
Pacific Biosciences: minus 11.73 percent, market capitalization USD 537.7 million
Illumina (NASDAQ, USD): minus 2.01 percent, P/E 48.98, market capitalization USD 39.6 billion
Natera (NASDAQ, USD): minus 2.80 percent, market capitalization USD 56.7 billion
Stock stays below its yearly high
Pacific Biosciences traded at USD 1.73 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 11.73 percent from the previous close of USD 1.96. The price was 49.71 percent below the 52-week high of USD 3.44.
Pacific Biosciences market profile
- Company: Pacific Biosciences of California, Inc.
- ISIN: US69404D1081
- Ticker: PACB
- Primary exchange: Nasdaq
- Nasdaq price (as of October 16, 2026, 4:00 p.m. ET): USD 1.73
- Change versus prior close: minus 11.73 percent
- Market capitalization: USD 537.7 million (as of October 16, 2026)
- 52-week range: USD 1.07-3.44 (as of October 16, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report S&P 500.
